Experimental inhibition of the AXL pathway with dominant negative-mutant glioma cells of the AXL receptor (SF126 AXL-DN) results in reduced glioma growth and prolonged survival in the orthotopic tumor model in mice [14]. This evidence concerns the gene AXL and glioma.